摘要
目的:评价3种用药方案治疗甲状腺功能亢进的经济性。方法:收集我院2016年全年诊疗的564例甲状腺功能亢进门诊患者的病历资料,按照用药方案分成A组(185例)、B组(191例)和C组(188例)。A组患者口服甲巯咪唑片2~4片,每天1次,视病情逐渐减量至0.5~2片;B组患者口服甲巯咪唑片(用法用量同A组)+抑亢丸6 g,每天2次;C组患者口服甲巯咪唑片(用法用量同A组)+夏枯草片6片,每天2次。3组患者疗程均为10个月。观察3组患者临床疗效、不良反应发生情况和复发情况,并运用药物经济学的成本-效果分析法对3种治疗方案进行经济学评价。结果:A、B、C组的总有效率分别为94.06%、95.29%、95.75%,总不良反应发生率分别为11.36%、10.48%、10.11%,差异均无统计学意义(P>0.05),3组患者均未出现复发情况。3组患者人均成本分别为633.80、3 548.89、3 596.00元,A组成本最低。敏感度分析结果显示亦为A组成本最低。结论:3种用药方案治疗甲状腺功能亢进的疗效与安全性均较好,其中甲巯咪唑单用方案具有较高的经济性。
OBJECTIVE：To evaluate the economical efficiency of 3 therapeutic regimens for hyperthyroidism. METHODS：Medical records of 564 hyperthyroid outpatients were selected from our hospital in 2016,and they were divided into group A（185 cases）,group B（191 cases）and group C（188 cases）according to drug use. Group A received Thiamazole tablets 2-4 tablet,once asthecondition gradually reduce th amount to 0.5-2 tablets orally;group B received Thiamazole tablets（cusage and dosage are the same as group A）＋Yikang pills 6 g,bid orally;group C received Thiamazole tablets（cusage and dosage are the same as group A）＋Xiakucao tablets 6 tablets,bid orally. The treatment courses of 3 groups lasted for 10 months. Clinical efficacy the occurrence of ADR and recurrence were observed in 3 groups.The pharmacoeconomic cost-effectiveness analysis was adopted for the economic evaluation of 3 therapeutic regimens. RESULTS：The tolal response rates of group A,B,C were 94.06%,95.29%,95.75%,respectively;total incidence of ADR were 11.36%,10.48%,10.11%;there was no statistical significance（P〈0.05）. No recurrence occurred in the 3 groups. The average cost of 3 groups were 633.80,3 548.89,3 596.00 yuan,respectively. The cost of group A was the lowest. The results of sensitivity analysis were also that the cost of group A was the lowest. CONCLUSIONS：3 therapeutic regimens show good therapeutic efficacy and safety for hyperthyroidism,among which thiamazole alone has relatively higher pharmacoeconomic significance.
出处
《中国药房》
CAS
北大核心
2018年第3期374-377,共4页
China Pharmacy
基金
广西壮族自治区卫生和计划生育委员会自筹经费科研课题(No.Z20170059)
